Neuroprotective properties of n-phenylacetyl-l-prolylglycine ethyl ester nasal gel in an experimental model of multiple sclerosis equivalent [Text] / B. S. Burlaka [et al.] // Медичні перспективи. - 2020. - Т. 25, № 4. - P31-38. - Bibliogr. at the end of the art. Рубрики: гель "Ноопепт" MeSH-головна: СКЛЕРОЗ РАССЕЯННЫЙ -- MULTIPLE SCLEROSIS (лекарственная терапия) ГЕЛИ -- GELS (анализ, терапевтическое применение, фармакокинетика) НАЗАЛЬНЫЕ СПРЕИ -- NASAL SPRAYS ЭТИЛОВЫЕ ЭФИРЫ -- ETHYL ETHERS (терапевтическое применение) Анотація: The purpose of this research is to study the specific activity of our developed nasal dosage form with n-phenylacetyl-l-prolylglycine ethyl ester. The experiments were performed on 260 white outbred rats weighing 190-220 g. Experimental allergic encephalomyelitis (EAE) was induced by a single subcutaneous inoculation of an encephalitogenic mixture (EHM) in Complete Freund’s Adjuvant (CFA) based on 100 mg of homologous spinal cord homogenate; 0.2 ml of CFA (the content of killed mycobacteria 5 mg/ml) and 0.2 ml of physiological saline per animal. There were five groups of animals in the study: 1) intact; 2) control - untreated with EAE, received saline solution; 3) animals with EAE that received basic treatment - methylprednisolone (MP), 3.4 mg/kg, intraperitoneally slowly in saline no more than 1/10 of the CBV rat; 4) animals with EAE treated with MP + Noopept, at a dose of 10 mg/kg; 5) animals with EAE treated with MP + Citicoline (Ceraxon, Ferrer Internacional S.A., Spain) D003U1 series, 500 mg/kg, intragastrically Дод.точки доступу: Burlaka, B. S. Belenichev, I. F. Nefedov, O. O. Aliyeva, O. G. Bukhtiyarova, N. V. Вільних прим. немає